http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Helix Specialty Diagnostics Partners with Genomic LTC DX to Provide COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
-
Fluidigm (FLDM) Receives CE-IVD Mark for Advanta Dx SARS-CoV-2 RT-PCR Assay
-
Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
-
Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results
-
New Data Published in Gastroenterology Demonstrate the Power of Fluidigm’s Imaging Mass Cytometry on the Hyperion Imaging System to Identify Novel Targets for Pancreatic Cancer Therapy
-
Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors
-
Fluidigm (FLDM) Announces Key Regulatory Body in India Grants Commercial License for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay
-
Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay
-
Fluidigm to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Study Utilizing Imaging Mass Cytometry Details Changes in Lung Tissue Architecture at the Single-Cell Level in Patients with COVID-19
-
Fluidigm COVID-19 Community Connect Program Builds a Network of Testing Partners to Increase Access of Saliva-Based SARS-CoV-2 Testing for Communities
-
Fluidigm to Present at Upcoming Health Care Investor Conference
-
Fluidigm Announces Third Quarter 2020 Financial Results
-
Fluidigm (FLDM), Healthvana Partner to Offer COVID-19 Test Results Delivery through Innovative Digital Platform
-
Fluidigm and Healthvana Partner to Offer COVID-19 Test Results Delivery through Innovative Digital Platform
-
Fluidigm Mass Cytometry Technologies, Including CyTOF, Imaging Mass Cytometry and Maxpar Direct, Utilized in More than 100 National Clinical Trials
-
Fluidigm (FLDM) Announces Dante Labs Launching COVID-19 Testing in Europe Utilizing Fluidigm Pathogen Detection Kit on Biomark HD Platform
-
Dante Labs Launching COVID-19 Testing in Europe Utilizing Fluidigm Pathogen Detection Kit on Biomark HD Platform
-
Fluidigm (FLDM) to Offer Millions of Advanta COVID-19 Tests at Low Cost to U.S. Colleges and Universities
-
Fluidigm to Offer Millions of Advanta COVID-19 Tests at Low Cost to U.S. Colleges and Universities
-
Fluidigm Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
-
Fluidigm Joins Global Consortium of Cancer Prevention Experts
-
Fluidigm (FLDM) Announces ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
-
ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
-
Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit
-
Fluidigm (FLDM) Achieves Initial Milestone under NIH Rapid Acceleration of Diagnostics Agreement
-
Fluidigm Achieves Initial Milestone under NIH Rapid Acceleration of Diagnostics Agreement
-
Fluidigm to Participate at the 2020 Cantor Virtual Global Healthcare Conference
-
Fluidigm (FLDM) Granted FDA EUA for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
-
Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
-
Fluidigm Announces Second Quarter 2020 Financial Results
-
Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis
-
Fluidigm (FLDM) Selected for $37 Million Project under National Institutes of Health RADx Initiative
-
Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative
-
Fluidigm (FLDM) Announces GnomeDX Files for FDA EUA for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing Fluidigm Biomark HD Platform
-
GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform
-
Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
-
Fluidigm (FLDM) Announces Multi-Site Study of COVID-19 Patients Utilizing Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay
-
Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay
-
Fluidigm (FLDM) Announces Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform
-
Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform
-
New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System
-
Fluidigm (FLDM) Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19 (Earlier)
-
Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19
-
University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19
-
Fluidigm to Present at Upcoming Health Care Investor Conferences
-
Fluidigm Announces First Quarter 2020 Financial Results
-
Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services
-
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results
-
Fluidigm (FLDM) Reports Prelim. 1Q Revenues Below Consensus; Withdraws FY20 Guidance
